Evoke Pharma and EVERSANA Announce the Appointment of Christopher Quesenberry as Chief Commercial Officer for Gimoti

Gimoti commercial launch on track for the fourth quarter of 2020

SOLANA BEACH, Calif. and CHICAGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases and EVERSANA, a leading provider of global commercial services to the life science industry, today announced that EVERSANA has appointed Christopher Quesenberry as Chief Commercial Officer for Gimoti. In June 2020, Gimoti was approved by the Food and Drug Administration for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis to which the companies have partnered commercialization.

Mr. Quesenberry brings over 30 years of experience in building and executing on commercial strategies for pharmaceutical companies and has held roles across the breadth of sales, marketing and operations. He previously spent 27 years between Novo Nordisk and Merck & Co. culminating in positions of Senior Director in Commercial Strategy, as well as Senior Sales Director in Commercial Operations, respectively. Recently, Mr. Quesenberry served as the Vice President of Global Commercial Effectiveness, providing leadership for Sales, Market Access, Sales Operations in addition to other commercial functions at Nalpropion Pharmaceuticals.

The commercialization collaboration between Evoke and EVERSANA calls for a wide collection of business functions to be headed by EVERSANA.  Mr. Quesenberry is leading the commercialization efforts across multiple functional teams driving senior decision making for strategy and guiding the building of the sales team amongst other responsibilities.  The coordination and breadth of commercial expertise within EVERSANA has showcased the benefits of this wide-ranging commercial partnership in terms of execution and efficiency.  The teams are rapidly implementing the original strategy and message for Gimoti as Evoke envisioned.

“In partnership with EVERSANA, we have been working to on-board an exceptional team of sales and marketing specialists in anticipation for the launch of Gimoti before and after our FDA approval earlier this year,” commented David Gonyer, R.Ph., President and CEO. “We are excited to bring on a seasoned professional such as Mr. Quesenberry and believe that he will be an invaluable addition as we continue to leverage EVERSANA’s integrated suite of capabilities and experts. We look forward to working with Chris in order to execute on our planned commercialization strategy as we plan to initiate sales for Gimoti in the fourth quarter of this year.”